IPO Details
Bidding Dates
23 Sep '25 - 25 Sep '25
Minimum Investment
₹2,80,000/ Lot (4,000 shares)
Price Range
₹65 – ₹70
Maximum Investment
₹2,80,000 /2 lots (4,000 Shares)
Retail Discount
To be announced
Issue Size
₹13.02 Cr
Investor category and sub category
Retail Individual Investors (RII) | Non-institutional Investors (NII) | Qualified Institutional Buyers (QIB) |Aptus Pharma IPO Important Dates
Important dates with respect to IPO allotment and listing
IPO Opening Date
Sep 23, 25
IPO Closing Date
Sep 25, 25
Basis of Allotment
Sep 26, 25
Initiation of Refunds
Sep 29, 25
IPO Listing Date
Sep 30, 25
Aptus Pharma IPO
Aptus Pharma IPO is a book-built issue with a total size of ₹13.02 crore. The issue comprises a fresh issue of 18.60 lakh shares aggregating up to ₹13.02 crore; there is no offer for sale.
The IPO will open for subscription on September 23, 2025, and close on September 25, 2025. The basis of allotment is expected to be finalized on September 26, 2025. The shares are proposed to be listed on the BSE SME, with a tentative listing date of September 30, 2025.
The price band for the IPO has been fixed between ₹65 and ₹70 per share. The lot size is set at 2,000 shares. A retail investor must apply for a minimum of 2 lots (4,000 shares), requiring an investment of ₹2,80,000 at the upper price band. For High Net-worth Individuals (HNIs), the minimum application is for 3 lots (6,000 shares), amounting to ₹4,20,000.
Interactive Financial Services Ltd. is the book running lead manager, Bigshare Services Pvt. Ltd. is the registrar, and Market-Hub Stock Broking Pvt. Ltd. is the market maker for this IPO.
Aptus Pharma IPO Objectives
The company plans to allocate the net proceeds from the issuance to the following purposes:
- The company will spend ₹162.95 lakhs from the issue proceeds towards capital expenditure, which includes acquiring new office premises at RK Trade Tower, Rajkot, along with furniture, modular office equipment, and heavy-duty industrial racks to enhance infrastructure and operational efficiency.
- The company has already made an advance payment of ₹10.51 lakhs for the office premises, with the total project cost estimated at ₹93.58 lakhs, covering purchase, maintenance, solar installation, GST, stamp duty, and registration fees.
- Additional funds under this head will be utilised for office furniture worth ₹48.02 lakhs and industrial racks worth ₹31.86 lakhs, sourced from suppliers in Rajkot.
- The company’s working capital requirements have grown significantly, with net working capital at ₹272.69 lakhs in FY23, ₹553.51 lakhs in FY24, and ₹1,538.88 lakhs in FY25, and are projected to reach ₹2,353 lakhs in FY26, reflecting its rapid scale-up and expansion strategy.
About Aptus Pharma Limited
Aptus Pharma Limited, incorporated in 2010 and headquartered in Ahmedabad, Gujarat, is engaged in the marketing and distribution of finished pharmaceutical formulations across a wide range of therapeutic areas. The company operates through a contract manufacturing model, collaborating with seven units—two under formal loan and license agreements and the rest on a purchase order basis.
Over the years, it has developed a diversified product portfolio of nearly 194 formulations spanning anti-infectives, gastrointestinal, cardiology, neuro-psychiatry, pain management, wellness, and nutraceuticals, offered in multiple dosage forms such as tablets, capsules, syrups, ointments, injections, and sachets.
Aptus Pharma maintains a strong distribution network of over 125 direct and sub-distributors supported by a field force of 54 sales personnel, with warehouses covering around 17,700 sq. ft. in Ahmedabad. Certified under ISO 9001:2015 and working with WHO-GMP compliant manufacturers, the company emphasises stringent quality checks and adherence to Good Distribution Practices (GDP).
Aptus Pharma Limited has shown strong financial growth in recent years. Total income rose from ₹13.90 crore in FY23 to ₹24.64 crore in FY25, while profit after tax jumped from ₹0.19 crore to ₹3.10 crore, marking a 288% rise year-on-year. EBITDA improved from ₹0.57 crore in FY23 to ₹4.76 crore in FY25, reflecting better operational efficiency. The company’s assets grew to ₹21.92 crore and net worth to ₹6.97 crore by FY25, though borrowings also increased to ₹10.36 crore, indicating higher leverage to support expansion.
Industry Outlook
- The global economy is projected to grow at 2.7% in 2025-26, but this pace is considered weak for sustaining long-term development.
- Emerging markets and developing economies (EMDEs), which drive 60% of global growth, face slower income convergence with advanced nations.
- Key risks include policy uncertainty, trade restrictions, geopolitical tensions, inflation, and climate-related disruptions, which may weigh on recovery.
- Global trade growth is expected to average 3.1% in 2025-26, supported by EMDEs, Japan, and the euro area, but still below pre-pandemic levels.
- Policymakers must focus on open trade, fiscal stability, climate action, and structural reforms like boosting human capital and labour participation to sustain growth.
How To Apply for the Aptus Pharma IPO Online?
- Log in to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
- Locate the IPO Section: Navigate to the 'IPO' section on the platform.
- Select IPO: Find and select the Aptus Pharma IPO from the list of open IPOs.
- Enter the Lot Size: Specify the number of lots you want to bid for.
- Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
- Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.
How To Check the Allotment Status of Aptus Pharma IPO?
Steps to check IPO allotment status on Angel One’s app:
- Log in to the Angel One app.
- Go to the IPO Section and then to IPO Orders.
- Select the individual IPO that you had applied for and check the allotment status.
- Angel One will notify you of your IPO allotment status via push notification and email.
Contact Details of Aptus Pharma Limited
Registered office: Ashutosh Buildcon, Opp. Slok - 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi, Ahmedabad, Gujarat, 382427
Phone: +91 76004 27827
E-mail:info@aptuspharma.com
Aptus Pharma IPO Reservation
|
Investor Category |
Shares Offered |
|
Market Maker Shares |
94,000 shares (5.05%) |
|
QIB Shares |
8,80,000 shares (47.31%) |
|
NII (HNI) Shares |
2,66,000 shares (14.30%) |
|
Retail Shares |
6,20,000 shares (33.33%) |
|
Total Shares |
18,60,000 shares (100%) |
Aptus Pharma IPO Lot Size Details
|
Application |
Lots |
Shares |
Amount (₹) |
|
Individual Investors (Retail) – Min |
2 |
4,000 |
₹2,80,000 |
|
Individual Investors (Retail) – Max |
2 |
4,000 |
₹2,80,000 |
|
S-HNI – Min |
3 |
6,000 |
₹4,20,000 |
|
S-HNI – Max |
7 |
14,000 |
₹9,80,000 |
|
B-HNI – Min |
8 |
16,000 |
₹11,20,000 |
Aptus Pharma IPO Promoter Holding
The promoters of the company include Tejash Maheshchandra Hathi, Chatrabhuj Vallabhbhai Butani, Kapilbhai Hasmukhbhai Chandarana, Ghanshyam Vinubhai Pansuriya, Milly Chetan Lalseta, Riddhish Natwarlal Tanna, Gaurang Rameshchandra Thakker, Kripaliben Mayank Thakker, and Kunjal Piyushbhai Unadkat.
|
Share Holding Pre-Issue |
100% |
|
Share Holding Post Issue |
72.89% |
Note: Equity dilution will be determined by subtracting the Shareholding Post Issue from the Shareholding Pre Issue.
Aptus Pharma IPO Anchor Investors Details
|
Particulars |
Details |
|
Bid Opening Date |
September 22, 2025 |
|
Total Shares Allotted |
5,28,000 shares |
|
Anchor Investor Portion |
₹3.70 crore |
|
Lock-in End Date for 50% of Shares (30 Days) |
October 26, 2025 |
|
Lock-in End Date for Remaining 50% of Shares (90 Days) |
December 25, 2025 |
Key Performance Indicators for Aptus Pharma IPO
|
KPI |
Value |
|
ROE (%) |
44.50% |
|
RoCE (%) |
45.66% |
|
Debt/Equity |
1.49 |
|
RoNW (%) |
44.50% |
|
PAT Margin (%) |
12.58% |
|
EBITDA Margin (%) |
19.31% |
Aptus Pharma IPO Prospectus
Aptus Pharma IPO Registrar and Lead Managers
Aptus Pharma IPO Lead Managers
- INTERACTIVE FINANCIAL SERVICES LIMITED
Registrar for Aptus Pharma IPO
Bigshare Services Private Limited
- Contact Number: +91-22-6263 8200
- Email Address: ipo@bigshareonline.com
Financial Performance of Aptus Pharma Limited
| Particulars | Year ending on March 31, 2025 | Year ending on March 31, 2024 | Year ending on March 31, 2023 |
|---|---|---|---|
| Revenue from Operation (in ₹ lakh) | 2,455.77 | 1,785.70 | 1,389.73 |
| Assets (₹ Cr) | 21.92 | 10.03 | 6.22 |
| Total Income (₹ Cr) | 24.64 | 17.88 | 13.90 |
| Profit After Tax (PAT) (₹ Cr) | 3.10 | 0.80 | 0.19 |
| EBITDA (₹ Cr) | 4.76 | 1.49 | 0.57 |
| Net Worth (₹ Cr) | 6.97 | 1.77 | 0.97 |
| Reserves & Surplus (₹ Cr) | 1.97 | 1.47 | 0.67 |
Know before investing
Strengths
6-
Diversified product portfolio spanning over 194 pharmaceutical formulations across more than 11 therapeutic segments, catering to a wide range of patient needs.
-
Robust and responsive distribution network with centrally located warehouses in Ahmedabad and an extensive team of over 54 field sales professionals, ensuring wide geographical coverage especially within Gujarat and West Bengal.
-
Asset-light business model relying on strategic contract manufacturing partnerships with seven third-party manufacturers, enabling operational flexibility and cost efficiency.
-
Commitment to high-quality standards with WHO-GMP certifications, stringent quality control protocols, and regular audits of manufacturing partners.
-
Experienced and visionary management team with deep pharmaceutical industry expertise, providing strong leadership and strategic direction.
-
Strong customer satisfaction and retention driven by consistent product quality, service responsiveness, and ethical business practices.
Risks
6-
The company does not have its own manufacturing facilities and relies on third-party contract manufacturers. Any disruption in supply, quality issues, or delays by these manufacturers could negatively impact operations.
-
The business requires multiple statutory and regulatory approvals that need timely renewal. Failure to obtain, renew or maintain these permits could lead to operational disruption or penalties.
-
A significant portion of revenue comes from a few customers. Loss of any major customer or contract termination could severely impact business and financial results.
-
A slowdown in India's economy or global economic instability could adversely affect the company’s business, cash flows, and growth prospects.
-
Economic or political instability worldwide, especially in countries where customers or partners operate, might affect business adversely.
-
Changes in government policies, political instability, or economic reforms could impact the company’s operations and share price.
Login to Angel One App / Website & click on IPO
Select desired IPO & tap on "Apply"
Enter UPI ID, set quantity/price & submit
Accept mandate on the UPI app to complete the process
Login to Angel One App / Website
Choose IPO section on Home Page
Click IPO Orders
Chose the IPO application you want to view the status for
Aptus Pharma Limited Peer Comparison
| Company | EPS | PE Ratio | RONW (%) | Revenue from Operation (₹ Cr) |
|---|---|---|---|---|
| Aptus Pharma Limited | NA | 5.32 | 44.50 | 2,455.77 |
| Zota Health Care Limited | 3.16 | 382.12 | 2.72 | 25,727.61 |
| Sunrest Lifescience Limited | 4.66 | 10.56 | 12.36 | 3,312.24 |
| Lincoln Pharmaceuticals Limited | 41.11 | 13.53 | 12.26 | 62,323.01 |
Aptus Pharma IPO FAQs
Aptus Pharma IPO is a book-built issue IPO. It runs from September 23, 2025, to September 25, 2025.
The Basis of Allotment will happen on Wednesday, September 26, 2025.
The IPO subscription window will open on September 23, 2025.
For an individual retail investor, the minimum investment required is ₹2,80,000 (equivalent to 4,000 shares at the upper price).
The listing date for Aptus Pharma IPO is Friday, September 30, 2025.
The issue size of the Aptus Pharma IPO is ₹13.02 crore.
The open and close dates for Aptus Pharma IPO are from September 23, 2025, to September 25, 2025.
Listing gains cannot be ascertained before the listing of the IPO on the stock exchange.
- Multiple Submissions: Use different Demat accounts to make multiple applications.
- Higher Price Band Bidding: Opt for bidding at the cut-off price or higher price band.
- Timely Subscription: Ensure you subscribe to the IPO within the specified time frame.
You must complete the payment process by logging in to your UPI handle and approving the payment mandate.
You can submit only one application using your PAN card.
To read Aptus Pharma Limited’s financial statements, download the IPO’s RHP document.
Pre-apply allows investors to apply for the Aptus Pharma IPO two days before the subscription period opens, ensuring an early submission of your application.
Your order will be placed when the IPO opens for bidding, and a UPI request will follow within 24 hours.
You will receive a notification once your order is successfully placed with the exchange after the bidding starts.
Bigshare Services Private Limited is the registrar responsible for managing the IPO allotment process and handling investor queries.
The Aptus Pharma IPO is proposed to be listed on the SME platform of the Bombay Stock Exchange (BSE).
